Page 199 - pharma 1 theoretical updated MNU_Neat

Clinical pharmacy 2024/2025 Level 3 Pharm D Pharmacology 1 (PO 502)

Hemolytic Anemia

1-Patients with G6PD deficiency
A. should avoid use of precipitating oxidant medications and chemicals.

B. No specific therapy compensates for this enzyme deficiency.
C. Steroids and other immunosuppressive agents have been used for the management of
autoimmune hemolytic anemias.
D. A splenectomy is sometimes indicated in an attempt to reduce RBC destruction.

2- Anemias caused by abnormal hemoglobin synthesis

A) sideroblastic anemia: microcytic &
can be congenital (hereditary, sex linked in males) or acquired

 Severe cases of SBA, bone marrow transplant with limited

information about the success rate.
Treatment  In the case of isoniazid-induced sideroblastic anemia ➔, the addition
of B6 is sufficient to correct the anemia.

 Desferrioxamine is used to treat iron overload from transfusions

B) overproduction of Heme precursors ➔ porphyria:
The most common form, acute intermittent porphyria (AIP),

Barbiturates, estrogens, alcohol, and heavy metals (e.g., lead) ➔
Pathophysiology
induce porphyria in susceptible people

Acute porphyrias
➢ IV sugar (glucose) - Intravenous fluids to combat dehydration
1- Injections of hemin, a medication that is a form of heme, to limit the

body's production of porphyrin
Cutaneous porphyrias
TTT ➢ Reducing exposure to sunlight and the amount of porphyrins in

your body to help eliminate your symptoms.
1- Drawing blood (phlebotomy)
2- Medication: Drugs used to treat malaria - hydroxychloroquine

3- Beta carotene: Reducing or eliminating triggers:
4- Vitamin D

| P a g e 183